“There are 26 Italian medical and research centers involved in the clinical development path of Isatuximab and this makes us very proud”. This was said by the President and CEO of Sanofi Italy, Marcello Cattani on the sidelines of the conference dedicated to the avant-garde in the treatment of multiple myeloma.